RxDoctor Payments Data

Lillian Borrego Conde, MD

Nephrology · Naranjito, PRNPI 1255417283

Payments from drug & device makers

$1,041in general payments, 2019–2025

Across 31 payments — averaging $33.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$266
  • PBG Puerto Rico LLC$167
  • Nxstage Medical, Inc.$147
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$100
  • Mallinckrodt Hospital Products Inc.$75
  • Boehringer Ingelheim$48
  • plus $238 from 8 others

What the payments were for

  • Food & beverage$86683%
  • Education$17517%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,041 in reported general payments places this provider in the 25th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$32,487
Medicare patients
78
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol129$97,041
TrulicityDulaglutide54$53,438
OzempicSemaglutide54$52,948
JardianceEmpagliflozin36$36,409
Sevelamer Carbonate266$34,981
LokelmaSodium Zirconium Cyclosilicate34$29,307
Calcium Acetate229$28,249
TradjentaLinagliptin34$23,950
Lanthanum Carbonate34$20,718
MounjaroTirzepatide12$16,915
KerendiaFinerenone15$13,792
EliquisApixaban16$12,220
RetacritEpoetin Alfa-Epbx23$9,957
SynthroidLevothyroxine Sodium70$4,971
LantusInsulin Glargine,hum.Rec.Anlog45$3,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$266$126,348163 claims
Boehringer IngelheimJardiance, Tradjenta$48$60,35970 claims
BayerKerendia$20$13,79215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Naranjito

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →